Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport[S]

The mechanism by which cholesteryl ester transfer protein (CETP) activity affects HDL metabolism was investigated using agents that selectively target CETP (dalcetrapib, torcetrapib, anacetrapib). In contrast with torcetrapib and anacetrapib, dalcetrapib requires cysteine 13 to decrease CETP activit...

Full description

Bibliographic Details
Main Authors: Eric J. Niesor, Christine Magg, Naoto Ogawa, Hiroshi Okamoto, Elisabeth von der Mark, Hugues Matile, Georg Schmid, Roger G. Clerc, Evelyne Chaput, Denise Blum-Kaelin, Walter Huber, Ralf Thoma, Philippe Pflieger, Makoto Kakutani, Daisuke Takahashi, Gregor Dernick, Cyrille Maugeais
Format: Article
Language:English
Published: Elsevier 2010-12-01
Series:Journal of Lipid Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520313559
id doaj-6b0ce888f3634531a2b4ff3ba44e3457
record_format Article
spelling doaj-6b0ce888f3634531a2b4ff3ba44e34572021-04-28T05:57:31ZengElsevierJournal of Lipid Research0022-22752010-12-01511234433454Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport[S]Eric J. Niesor0Christine Magg1Naoto Ogawa2Hiroshi Okamoto3Elisabeth von der Mark4Hugues Matile5Georg Schmid6Roger G. Clerc7Evelyne Chaput8Denise Blum-Kaelin9Walter Huber10Ralf Thoma11Philippe Pflieger12Makoto Kakutani13Daisuke Takahashi14Gregor Dernick15Cyrille Maugeais16To whom correspondence should be addressed. eric_j.niesor@roche.com; Pharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandPharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandCentral Pharmaceutical Research Institute, Japan Tobacco, Inc., Osaka, JapanCentral Pharmaceutical Research Institute, Japan Tobacco, Inc., Osaka, JapanPharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandPharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandPharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandPharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandPharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandPharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandPharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandPharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandPharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandCentral Pharmaceutical Research Institute, Japan Tobacco, Inc., Osaka, JapanCentral Pharmaceutical Research Institute, Japan Tobacco, Inc., Osaka, JapanPharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandPharmaceuticals Division, F. Hoffmann-La Roche Ltd, Basel, SwitzerlandThe mechanism by which cholesteryl ester transfer protein (CETP) activity affects HDL metabolism was investigated using agents that selectively target CETP (dalcetrapib, torcetrapib, anacetrapib). In contrast with torcetrapib and anacetrapib, dalcetrapib requires cysteine 13 to decrease CETP activity, measured as transfer of cholesteryl ester (CE) from HDL to LDL, and does not affect transfer of CE from HDL3 to HDL2. Only dalcetrapib induced a conformational change in CETP, when added to human plasma in vitro, also observed in vivo and correlated with CETP activity. CETP-induced pre-β-HDL formation in vitro in human plasma was unchanged by dalcetrapib ≤3 µM and increased at 10 µM. A dose-dependent inhibition of pre-β-HDL formation by torcetrapib and anacetrapib (0.1 to 10 µM) suggested that dalcetrapib modulates CETP activity. In hamsters injected with [3H]cholesterol-labeled autologous macrophages, and given dalcetrapib (100 mg twice daily), torcetrapib [30 mg once daily (QD)], or anacetrapib (30 mg QD), only dalcetrapib significantly increased fecal elimination of both [3H]neutral sterols and [3H]bile acids, whereas all compounds increased plasma HDL-[3H]cholesterol. These data suggest that modulation of CETP activity by dalcetrapib does not inhibit CETP-induced pre-β-HDL formation, which may be required to increase reverse cholesterol transport.http://www.sciencedirect.com/science/article/pii/S0022227520313559dalcetrapibtorcetrapibanacetrapibhigh density lipoprotein-functionalityapolipoproteinsbile acids and salts/metabolism
collection DOAJ
language English
format Article
sources DOAJ
author Eric J. Niesor
Christine Magg
Naoto Ogawa
Hiroshi Okamoto
Elisabeth von der Mark
Hugues Matile
Georg Schmid
Roger G. Clerc
Evelyne Chaput
Denise Blum-Kaelin
Walter Huber
Ralf Thoma
Philippe Pflieger
Makoto Kakutani
Daisuke Takahashi
Gregor Dernick
Cyrille Maugeais
spellingShingle Eric J. Niesor
Christine Magg
Naoto Ogawa
Hiroshi Okamoto
Elisabeth von der Mark
Hugues Matile
Georg Schmid
Roger G. Clerc
Evelyne Chaput
Denise Blum-Kaelin
Walter Huber
Ralf Thoma
Philippe Pflieger
Makoto Kakutani
Daisuke Takahashi
Gregor Dernick
Cyrille Maugeais
Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport[S]
Journal of Lipid Research
dalcetrapib
torcetrapib
anacetrapib
high density lipoprotein-functionality
apolipoproteins
bile acids and salts/metabolism
author_facet Eric J. Niesor
Christine Magg
Naoto Ogawa
Hiroshi Okamoto
Elisabeth von der Mark
Hugues Matile
Georg Schmid
Roger G. Clerc
Evelyne Chaput
Denise Blum-Kaelin
Walter Huber
Ralf Thoma
Philippe Pflieger
Makoto Kakutani
Daisuke Takahashi
Gregor Dernick
Cyrille Maugeais
author_sort Eric J. Niesor
title Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport[S]
title_short Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport[S]
title_full Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport[S]
title_fullStr Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport[S]
title_full_unstemmed Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport[S]
title_sort modulating cholesteryl ester transfer protein activity maintains efficient pre-β-hdl formation and increases reverse cholesterol transport[s]
publisher Elsevier
series Journal of Lipid Research
issn 0022-2275
publishDate 2010-12-01
description The mechanism by which cholesteryl ester transfer protein (CETP) activity affects HDL metabolism was investigated using agents that selectively target CETP (dalcetrapib, torcetrapib, anacetrapib). In contrast with torcetrapib and anacetrapib, dalcetrapib requires cysteine 13 to decrease CETP activity, measured as transfer of cholesteryl ester (CE) from HDL to LDL, and does not affect transfer of CE from HDL3 to HDL2. Only dalcetrapib induced a conformational change in CETP, when added to human plasma in vitro, also observed in vivo and correlated with CETP activity. CETP-induced pre-β-HDL formation in vitro in human plasma was unchanged by dalcetrapib ≤3 µM and increased at 10 µM. A dose-dependent inhibition of pre-β-HDL formation by torcetrapib and anacetrapib (0.1 to 10 µM) suggested that dalcetrapib modulates CETP activity. In hamsters injected with [3H]cholesterol-labeled autologous macrophages, and given dalcetrapib (100 mg twice daily), torcetrapib [30 mg once daily (QD)], or anacetrapib (30 mg QD), only dalcetrapib significantly increased fecal elimination of both [3H]neutral sterols and [3H]bile acids, whereas all compounds increased plasma HDL-[3H]cholesterol. These data suggest that modulation of CETP activity by dalcetrapib does not inhibit CETP-induced pre-β-HDL formation, which may be required to increase reverse cholesterol transport.
topic dalcetrapib
torcetrapib
anacetrapib
high density lipoprotein-functionality
apolipoproteins
bile acids and salts/metabolism
url http://www.sciencedirect.com/science/article/pii/S0022227520313559
work_keys_str_mv AT ericjniesor modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports
AT christinemagg modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports
AT naotoogawa modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports
AT hiroshiokamoto modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports
AT elisabethvondermark modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports
AT huguesmatile modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports
AT georgschmid modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports
AT rogergclerc modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports
AT evelynechaput modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports
AT deniseblumkaelin modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports
AT walterhuber modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports
AT ralfthoma modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports
AT philippepflieger modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports
AT makotokakutani modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports
AT daisuketakahashi modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports
AT gregordernick modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports
AT cyrillemaugeais modulatingcholesterylestertransferproteinactivitymaintainsefficientprebhdlformationandincreasesreversecholesteroltransports
_version_ 1721504842682204160